177 related articles for article (PubMed ID: 28498618)
21. Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer.
Suzuki H; Fukuhara M; Yamaura T; Mutoh S; Okabe N; Yaginuma H; Hasegawa T; Yonechi A; Osugi J; Hoshino M; Kimura T; Higuchi M; Shio Y; Ise K; Takeda K; Gotoh M
J Transl Med; 2013 Apr; 11():97. PubMed ID: 23578144
[TBL] [Abstract][Full Text] [Related]
22. Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme.
Terasaki M; Shibui S; Narita Y; Fujimaki T; Aoki T; Kajiwara K; Sawamura Y; Kurisu K; Mineta T; Yamada A; Itoh K
J Clin Oncol; 2011 Jan; 29(3):337-44. PubMed ID: 21149665
[TBL] [Abstract][Full Text] [Related]
23. Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer.
Asahara S; Takeda K; Yamao K; Maguchi H; Yamaue H
J Transl Med; 2013 Nov; 11():291. PubMed ID: 24237633
[TBL] [Abstract][Full Text] [Related]
24. [Peptide vaccination for castration-resistant prostate cancer].
Koga N; Noguchi M
Nihon Rinsho; 2014 Dec; 72(12):2147-51. PubMed ID: 25518349
[TBL] [Abstract][Full Text] [Related]
25. Immunological evaluation of CTL precursor-oriented vaccines for advanced lung cancer patients.
Mine T; Gouhara R; Hida N; Imai N; Azuma K; Rikimaru T; Katagiri K; Nishikori M; Sukehiro A; Nakagawa M; Yamada A; Aizawa H; Shirouzu K; Itoh K; Yamana H
Cancer Sci; 2003 Jun; 94(6):548-56. PubMed ID: 12824881
[TBL] [Abstract][Full Text] [Related]
26. Telomerase-based GX301 cancer vaccine in patients with metastatic castration-resistant prostate cancer: a randomized phase II trial.
Filaci G; Fenoglio D; Nolè F; Zanardi E; Tomasello L; Aglietta M; Del Conte G; Carles J; Morales-Barrera R; Guglielmini P; Scagliotti G; Signori A; Parodi A; Kalli F; Astone G; Ferrera F; Altosole T; Lamperti G; Criscuolo D; Gianese F; Boccardo F
Cancer Immunol Immunother; 2021 Dec; 70(12):3679-3692. PubMed ID: 34351436
[TBL] [Abstract][Full Text] [Related]
27. Phase I trial of patient-oriented vaccination in HLA-A2-positive patients with metastatic hormone-refractory prostate cancer.
Noguchi M; Itoh K; Suekane S; Yao A; Suetsugu N; Katagiri K; Yamada A; Yamana H; Noda S
Cancer Sci; 2004 Jan; 95(1):77-84. PubMed ID: 14720331
[TBL] [Abstract][Full Text] [Related]
28. Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer.
Aruga A; Takeshita N; Kotera Y; Okuyama R; Matsushita N; Ohta T; Takeda K; Yamamoto M
J Transl Med; 2014 Mar; 12():61. PubMed ID: 24606884
[TBL] [Abstract][Full Text] [Related]
29. The feasibility of Cep55/c10orf3 derived peptide vaccine therapy for colorectal carcinoma.
Inoda S; Morita R; Hirohashi Y; Torigoe T; Asanuma H; Nakazawa E; Nakatsugawa M; Tamura Y; Kamiguchi K; Tsuruma T; Terui T; Ishitani K; Hashino S; Wang Q; Greene MI; Hasegawa T; Hirata K; Asaka M; Sato N
Exp Mol Pathol; 2011 Feb; 90(1):55-60. PubMed ID: 20950610
[TBL] [Abstract][Full Text] [Related]
30. Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients.
Kameshima H; Tsuruma T; Torigoe T; Takahashi A; Hirohashi Y; Tamura Y; Tsukahara T; Ichimiya S; Kanaseki T; Iwayama Y; Sato N; Hirata K
Cancer Sci; 2011 Jun; 102(6):1181-7. PubMed ID: 21371173
[TBL] [Abstract][Full Text] [Related]
31. Potential survival benefit of anti-apoptosis protein: survivin-derived peptide vaccine with and without interferon alpha therapy for patients with advanced or recurrent urothelial cancer--results from phase I clinical trials.
Tanaka T; Kitamura H; Inoue R; Nishida S; Takahashi-Takaya A; Kawami S; Torigoe T; Hirohashi Y; Tsukamoto T; Sato N; Masumori N
Clin Dev Immunol; 2013; 2013():262967. PubMed ID: 24363758
[TBL] [Abstract][Full Text] [Related]
32. Haptoglobin promoter polymorphism rs5472 as a prognostic biomarker for peptide vaccine efficacy in castration-resistant prostate cancer patients.
Araki H; Pang X; Komatsu N; Soejima M; Miyata N; Takaki M; Muta S; Sasada T; Noguchi M; Koda Y; Itoh K; Kuhara S; Tashiro K
Cancer Immunol Immunother; 2015 Dec; 64(12):1565-73. PubMed ID: 26428930
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapeutic benefit of α-interferon (IFNα) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients.
Kameshima H; Tsuruma T; Kutomi G; Shima H; Iwayama Y; Kimura Y; Imamura M; Torigoe T; Takahashi A; Hirohashi Y; Tamura Y; Tsukahara T; Kanaseki T; Sato N; Hirata K
Cancer Sci; 2013 Jan; 104(1):124-9. PubMed ID: 23078230
[TBL] [Abstract][Full Text] [Related]
34. Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer.
Miyazaki A; Kobayashi J; Torigoe T; Hirohashi Y; Yamamoto T; Yamaguchi A; Asanuma H; Takahashi A; Michifuri Y; Nakamori K; Nagai I; Sato N; Hiratsuka H
Cancer Sci; 2011 Feb; 102(2):324-9. PubMed ID: 21143701
[TBL] [Abstract][Full Text] [Related]
35. Phase I/II clinical trial to assess safety and efficacy of intratumoral and subcutaneous injection of HVJ-E in castration-resistant prostate cancer patients.
Fujita K; Nakai Y; Kawashima A; Ujike T; Nagahara A; Nakajima T; Inoue T; Lee CM; Uemura M; Miyagawa Y; Kaneda Y; Nonomura N
Cancer Gene Ther; 2017 Jul; 24(7):277-281. PubMed ID: 28497777
[TBL] [Abstract][Full Text] [Related]
36. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.
Fizazi K; Massard C; Bono P; Jones R; Kataja V; James N; Garcia JA; Protheroe A; Tammela TL; Elliott T; Mattila L; Aspegren J; Vuorela A; Langmuir P; Mustonen M;
Lancet Oncol; 2014 Aug; 15(9):975-85. PubMed ID: 24974051
[TBL] [Abstract][Full Text] [Related]
37. A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer.
Noguchi M; Uemura H; Naito S; Akaza H; Yamada A; Itoh K
Prostate; 2011 Apr; 71(5):470-9. PubMed ID: 20878951
[TBL] [Abstract][Full Text] [Related]
38. Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer.
Noguchi M; Yao A; Harada M; Nakashima O; Komohara Y; Yamada S; Itoh K; Matsuoka K
Prostate; 2007 Jun; 67(9):933-42. PubMed ID: 17440952
[TBL] [Abstract][Full Text] [Related]
39. A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome.
Hazama S; Nakamura Y; Takenouchi H; Suzuki N; Tsunedomi R; Inoue Y; Tokuhisa Y; Iizuka N; Yoshino S; Takeda K; Shinozaki H; Kamiya A; Furukawa H; Oka M
J Transl Med; 2014 Mar; 12():63. PubMed ID: 24612787
[TBL] [Abstract][Full Text] [Related]
40. Vaccination with predesignated or evidence-based peptides for patients with recurrent gynecologic cancers.
Tsuda N; Mochizuki K; Harada M; Sukehiro A; Kawano K; Yamada A; Ushijima K; Sugiyama T; Nishida T; Yamana H; Itoh K; Kamura T
J Immunother; 2004; 27(1):60-72. PubMed ID: 14676634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
